The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial
Open accessAbstract
Importance: Anakinra, an interleukin 1β recombinant receptor antagonist, may have potential to treat colchicine-resistant and corticosteroid-dependent recurrent pericarditis. Objective: To determine the efficacy of anakinra for colchicine-resistant and corticosteroid-dependent recurrent pericarditis. Design, Setting, and Participants: The Anakinra-Treatment of Recurrent Idiopathic Pericarditis (AIRTRIP) double-blind, placebo-controlled, randomized withdrawal trial (open label with anakinra followed by a double-blind withdrawal step with anakinra or placebo until recurrent pericarditis occurred) conducted among 21 consecutive patients enrolled at 3 Italian referral centers between June and November 2014 (end of follow-up, October 2015). Included patients had recurrent pericarditis (with ≥3 previous recurrences), elevation of C-reactive protein, colchicine resistance, and corticosteroid dependence. Interventions: Anakinra was administered at 2 mg/kg per day, up to 100 mg, for 2 months, then patients who responded with resolution of pericarditis were randomized to continue anakinra (n = 11) or switch to placebo (n = 10) for 6 months or until a pericarditis recurrence. Main Outcomes and Measures: The primary outcomes were recurrent pericarditis and time to recurrence after randomization. Results: Eleven patients (7 female) randomized to anakinra had a mean age of 46.5 (SD, 16.3) years; 10 patients (7 female) randomized to placebo had a mean age of 44 (SD, 12.5) years. All patients were followed up for 12 months. Median follow-up was 14 (range, 12-17) months. Recurrent pericarditis occurred in 9 of 10 patients (90%; incidence rate, 2.06% of patients per year) assigned to placebo and 2 of 11 patients (18.2%; incidence rate, 0.11% of patients per year) assigned to anakinra, for an incidence rate difference of -1.95% (95% CI, -3.3% to -0.6%). Median flare-free survival (time to flare) was 72 (interquartile range, 64-150) days after randomization in the placebo group and was not reached in the anakinra group (P <.001). During anakinra treatment, 20 of 21 patients (95.2%) experienced transient local skin reactions: 1 (4.8%) herpes zoster, 3 (14.3%) transaminase elevation, and 1 (4.8%) ischemic optic neuropathy. No patient permanently discontinued the active drug. No adverse events occurred during placebo treatment. Conclusion and Relevance: In this preliminary study of patients with recurrent pericarditis with colchicine resistance and corticosteroid dependence, the use of anakinra compared with placebo reduced the risk of recurrence over a median of 14 months. Larger studies are needed to replicate these findings as well as to assess safety and longer-term efficacy. Trial Registration: clinicaltrials.gov Identifier: NCT02219828.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2015 ESC Guidelines for the diagnosis and management of pericardial diseases
Adler, Y., Charron, P., Imazio, M., Badano, L., Barón-Esquivias, G., Bogaert, J., Brucato, A., Gueret, P., Klingel, K., Lionis, C., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv318 · Cited by 2,634
Self-citationA Randomized Trial of Colchicine for Acute Pericarditis
Imazio, M., Brucato, A., Cemin, R., Ferrua, S., Maggiolini, S., Beqaraj, F., Demarie, D., Forno, D., Ferro, S., Maestroni, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208536 · Cited by 611
Self-citationSalliot, C., Dougados, M., & Gossec, L. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.083188 · Cited by 477
Evaluation and Treatment of Pericarditis: A Systematic Review
Imazio, M., Gaita, F., & LeWinter, M. (2015) · JAMA · doi:10.1001/jama.2015.12763 · Cited by 452
Self-citationImazio, M., Belli, R., Brucato, A., Cemin, R., Ferrua, S., Beqaraj, F., Demarie, D., Ferro, S., Forno, D., Maestroni, S., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62709-9 · Cited by 406
Self-citationColchicine for Recurrent Pericarditis (CORP): A Randomized Trial
Imazio, M., Brucato, A., Cemin, R., Ferrua, S., Belli, R., Maestroni, S., Trinchero, R., Spodick, D. H., Adler, Y., & on behalf of the CORP (COlchicine for Recurrent Pericarditis) Investigators* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-7-201110040-00359 · Cited by 389
Self-citationCampion, G. V., Lebsack, M. E., Lookabaugh, J., & Gordon, G. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780390704 · Cited by 247
LeWinter, M. M. (2014) · New England Journal of Medicine · doi:10.1056/nejmcp1404070 · Cited by 211
Picco, P. P., Brisca, G., Traverso, F., Loy, A., Gattorno, M., & Martini, A. (2008) · Arthritis & Rheumatism · doi:10.1002/art.24174 · Cited by 167
Self-citationFILOCAMO, G., DAVÌ, S., PISTORIO, A., BERTAMINO, M., RUPERTO, N., LATTANZI, B., CONSOLARO, A., MAGNI-MANZONI, S., GALASSO, R., VARNIER, G. C., et al. (2010) · The Journal of Rheumatology · doi:10.3899/jrheum.091474 · Cited by 161
Self-citationFinetti, M., Insalaco, A., Cantarini, L., Meini, A., Breda, L., Alessio, M., D’Alessandro, M., Picco, P. P., Martini, A., & Gattorno, M. (2014) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2014.01.065 · Cited by 127
Self-citationSafety of biologic therapy in rheumatoid arthritis
Woodrick, R. S., & Ruderman, E. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.145 · Cited by 85
Effectiveness and Safety of Anakinra for Management of Refractory Pericarditis
Jain, S., Thongprayoon, C., Espinosa, R. E., Hayes, S. N., Klarich, K. W., Cooper, L. T., Moder, K. G., Anavekar, N. S., Oh, J. K., & Matteson, E. L. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.07.047 · Cited by 72
Lazaros, G. A., Imazio, M., Brucato, A. L., Vassilopoulos, D., Vasileiou, P. V. S., Gattorno, M., Tousoulis, D. M., & Martini, A. (2015) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000266 · Cited by 63
Self-citationCantarini, L., Lucherini, O. M., Cimaz, R., & Galeazzi, M. (2010) · PubMed · Cited by 55
Scott, I. C., Hajela, V., Hawkins, P. N., & Lachmann, H. J. (2011) · Journal of Cardiology Cases · doi:10.1016/j.jccase.2011.07.003 · Cited by 34
Cited by
Myocarditis and inflammatory cardiomyopathy: current evidence and future directions
Tschöpe, C., Ammirati, E., Bozkurt, B., Caforio, A. L. P., Cooper, L. T., Felix, S. B., Hare, J. M., Heidecker, B., Heymans, S., Hübner, N., et al. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00435-x · Cited by 1,217
Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease
Abbate, A., Toldo, S., Marchetti, C., Kron, J., Van Tassell, B. W., & Dinarello, C. A. (2020) · Circulation Research · doi:10.1161/circresaha.120.315937 · Cited by 730
2025 ESC Guidelines for the management of myocarditis and pericarditis
Schulz-Menger, J., Collini, V., Gröschel, J., Adler, Y., Brucato, A., Christian, V., Ferreira, V. M., Gandjbakhch, E., Heidecker, B., Kerneis, M., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf192 · Cited by 434
Self-citationThe role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases
Toldo, S., & Abbate, A. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00946-3 · Cited by 411
Management of Acute and Recurrent Pericarditis
Chiabrando, J. G., Bonaventura, A., Vecchié, A., Wohlford, G. F., Mauro, A. G., Jordan, J. H., Grizzard, J. D., Montecucco, F., Berrocal, D. H., Brucato, A., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.021 · Cited by 396
Self-citation
Metadata
- Authors
- Brucato, A., Imazio, M., Gattorno, M., Lazaros, G., Maestroni, S., Carraro, M., Finetti, M., Cumetti, D., Carobbio, A., Ruperto, N., Marcolongo, R., Lorini, M., Rimini, A., Valenti, A., Erre, G. L., Sormani, M. P., Belli, R., Gaita, F., & Martini, A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2016-11-08
- Volume
- 316
- Issue
- 18
- Pages
- 1906
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2551094451
- Cited by
- 401
- References
- 16
- FWCI
- 15.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.